

April 5, 2018



BioSig Technologies Issues 2018 Shareholder Letter

Highlights Include FDA 510(k) Submission and Insider Buying

Santa Monica, CA, April 05, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ([BSGM](#)) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the \$4.6 billion electrophysiology (EP) marketplace, today announced that the Company has officially issued their 2018 letter to its shareholders providing them with updates on commercialization efforts, strategic relationships and enhancements to capital structure.

Recent Company Highlights

- Announced the submission of its 510(k) application with the U.S. Food and Drug Administration (FDA) for clearance of the company's PURE EP™ technology
- Management filed Form 4 documents announcing their insider stock purchases
- Raised nearly \$9 million in equity for the company
- Reiterated goal to uplist to Nasdaq Stock Exchange

"I believe that with all of the recent developments we have made and commercialization efforts now underway, now is the ideal time to provide an in-depth update to the investment community," stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. "In addition to formally submitting our 510(k) application with the FDA and making strategic hires to our commercialization team, we have strengthened both our balance sheet and industry relationships. Proof of managements' optimism in the company can be seen from our numerous Form 4 filings, announcing significant insider stock purchases from our team. I am confident that the strides we have made over the last several months will allow us to uplist to a more senior exchange in the near future, as we remain focused on our principal objective, increasing shareholder value."

To view BioSig Technologies' Shareholder Letter please visit: [Link to Letter](#)

About BioSig Technologies

BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the \$4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles- based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The Company's first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat

patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

Natasha Russkina
BioSig Technologies, Inc.
VP Business Development & Corporate Finance
nrusskina@biosigtech.com
+41 (0) 76 823 7527



Source: BioSig Technologies, Inc.